Spruce Biosciences, Inc. (SPRB) shareholders
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$43.31+0.42 (+0.98%)
Close on Nov 13, 2026Market cap $124.47MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
69.7%
2M of 3M shares
Institutional holders
63
35 new, 4 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orin Hirschman Joint filing with AIGH Capital Management LLC (9.10%) | 250,000 | 9.10% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 187,836 | 6.80% | 13G (passive) | Jun 30, 2026 |
| Israel A. Englander Joint filing with Integrated Core Strategies (US) LLC (5.80%), Millennium Management LLC (5.80%) and 1 more | 160,981 | 5.80% | 13G (passive) amendment | Jun 30, 2026 |
| AWM Investment Company, Inc. | 146,988 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Neil Shahrestani Joint filing with Ikarian Capital, LLC (11.40%) | 121,356 | 11.40% | 13G (passive) amendment | Oct 31, 2025 |
| Citadel Advisors Holdings LP Joint filing with Citadel Advisors LLC (9.99%), Citadel GP LLC (9.99%) and 1 more | 109,649 | 9.99% | 13G (passive) | Oct 9, 2025 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (9.60%), Israel A. Englander (9.60%) and 1 more | 103,026 | 9.60% | 13G (passive) | Feb 17, 2026 |
| Matthew Sesterhenn Joint filing with Squadron Master Fund LP (6.50%), Squadron Capital Management LLC (6.50%) and 1 more | 70,000 | 6.50% | 13G (passive) amendment | Dec 31, 2025 |
| William Blank Joint filing with Squadron Capital Management LLC (6.60%), Matthew Sesterhenn (6.60%) and 1 more | 70,000 | 6.60% | 13G (passive) | Oct 8, 2025 |
| Boone Peter David Mr | 68,184 | 6.40% | 13G (passive) | Nov 21, 2025 |
| Daniel Schneeberger Joint filing with ADAR1 Capital Management, LLC (5.40%) | 58,000 | 5.40% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SPRB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 250,000 | 8.70% | $13.50M | New | 0.85% |
| Orbimed Advisors LLC | 200,000 | 6.96% | $10.80M | New | 0.20% |
| BlackRock, Inc. | 187,836 | 6.54% | $10.14M | +170,898 | 0.00% |
| Millennium Management LLC | 160,981 | 5.60% | $8.69M | +49,093 | 0.00% |
| Ikarian Capital, LLC | 121,356 | 4.22% | $6.55M | – | 0.71% |
| Vanguard Capital Management LLC | 119,331 | 4.15% | $6.44M | +100,994 | 0.00% |
| Alyeska Investment Group, L.P. | 81,671 | 2.84% | $4.41M | +30,000 | 0.01% |
| Geode Capital Management, LLC | 70,548 | 2.45% | $3.81M | +57,659 | 0.00% |
| ADAR1 Capital Management, LLC | 67,717 | 2.36% | $3.66M | +9,117 | 0.17% |
| Cable Car Capital, LP | 60,000 | 2.09% | $3.24M | New | 0.07% |
| Citadel Advisors LLC | 51,905 | 1.81% | $2.80M | −18,094 | 0.00% |
| State Street Corp | 50,450 | 1.76% | $2.72M | +45,050 | 0.00% |
| Boothbay Fund Management, LLC | 42,080 | 1.46% | $2.27M | – | 0.03% |
| Stempoint Capital LP | 41,388 | 1.44% | $2.23M | +28,668 | 0.38% |
| Eversept Partners, LP | 40,000 | 1.39% | $2.16M | New | 0.11% |
| Carlyle Group Inc. | 38,620 | 1.34% | $2.09M | – | 0.02% |
| Goldman Sachs Group Inc | 32,348 | 1.13% | $1.75M | +26,842 | 0.00% |
| Diadema Partners LP | 30,000 | 1.04% | $1.62M | +20,000 | 0.20% |
| Affinity Asset Advisors, LLC | 30,000 | 1.04% | $1.62M | New | 0.07% |
| Stonepine Capital Management, LLC | 28,795 | 1.00% | $1.55M | New | 0.88% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 63 | 2M | 69.7% | 35 / 16 | 3 / 4 | 1M | 0M |
| Q1 2026 | 32 | 1M | 26.0% | 10 / 6 | 6 / 9 | 0M | 0M |
| Q4 2025 | 32 | 1M | 26.2% | 25 / 4 | 1 / 2 | 1M | 3M |
| Q3 2025 | 9 | 3M | 100.0% | 7 / 2 | 0 / 1 | 3M | 0M |
| Q2 2025 | 3 | 0M | 0.0% | 0 / 0 | 0 / 28 | 0M | 0M |
| Q1 2025 | 31 | 0M | 0.1% | 5 / 4 | 2 / 5 | 0M | 0M |
| Q4 2024 | 31 | 0M | 0.1% | 6 / 3 | 6 / 4 | 0M | 0M |
| Q3 2024 | 30 | 0M | 0.1% | 1 / 5 | 10 / 8 | 0M | 0M |
| Q2 2024 | 38 | 0M | 0.1% | 5 / 5 | 12 / 17 | 0M | 0M |
| Q1 2024 | 50 | 0M | 0.1% | 22 / 8 | 8 / 12 | 0M | 0M |
| Q4 2023 | 40 | 0M | 0.2% | 4 / 5 | 9 / 5 | 0M | 0M |
| Q3 2023 | 41 | 0M | 0.2% | 2 / 10 | 7 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
53 funds held SPRB in Q2 2026, 85% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SPRB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 84,935 | 2.96% | $4.59M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 65,222 | 2.27% | $3.52M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 31,892 | 1.11% | $1.72M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 29,694 | 1.03% | $1.27M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 16,862 | 0.59% | $910.55K | 0.01% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 8,665 | 0.30% | $467.91K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 6,797 | 0.24% | $291.12K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 6,207 | 0.22% | $335.18K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 5,566 | 0.19% | $285.37K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 4,827 | 0.17% | $260.66K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 3,751 | 0.13% | $160.66K | 0.00% | Jul 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 3,660 | 0.13% | $156.76K | 0.00% | Jul 31, 2026 |
| Fidelity Small Cap Value Index Fund | 2,837 | 0.10% | $153.20K | 0.01% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 2,787 | 0.10% | $150.50K | 0.00% | Jun 30, 2026 |
| LVIP State Street Small-Cap Index Fund | 2,100 | 0.07% | $113.40K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER, Director | 19,270 | 0.67% | Jul 9, 2026 |
| Michael G. Grey | Executive Chairman, Director | – | – | May 26, 2026 |
| Douglas Kirk Ways | Interim Chief Medical Officer, Director | 1,250 | 0.04% | Jan 21, 2026 |
| Adrian W. Quartel | Chief Medical Officer | – | – | Jul 29, 2026 |
| Corwin Dale Hooks | Chief Commercial Officer | – | – | Mar 9, 2026 |
| Samir M. Gharib | PRESIDENT AND CFO | 8,263 | 0.29% | Dec 17, 2025 |
| Ralph William Charlton III | CHIEF MEDICAL OFFICER | 150,409 | 5.23% | Dec 20, 2024 |
| Daniel K. Spiegelman | Director | – | – | May 26, 2026 |
| Keli Walbert | Director | – | – | May 26, 2026 |
| Camilla V. Simpson | Director | 334 | 0.01% | May 26, 2026 |
| Percival Barretto-Ko | Director | 0 | – | May 26, 2026 |
| Tiba Aynechi | Director | – | – | Jul 24, 2025 |
| Bali Muralidhar | Director | 1,792,518 | 62.37% | Jul 24, 2025 |
| Healthcare Partners LLC Parkman | 10% owner | 1,051 | 0.04% | Oct 15, 2025 |
| Gregory Martinez | 10% owner | – | – | Oct 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Jun 30, 2026 | Award | +266 | $4.53 | $1.20K | 19,270 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 31, 2025 | Award | +4,690 | $4.53 | $21.25K | 19,004 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 15, 2025 | Option exercise | +1,196 | – | – | 14,922 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 15, 2025 | Option exercise | +1,480 | – | – | 14,478 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 15, 2025 | Tax withholding | −608 | $80.67 | $49.05K | 14,314 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 15, 2025 | Tax withholding | −752 | $80.67 | $60.66K | 13,726 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 15, 2025 | Tax withholding | −184 | $80.67 | $14.84K | 8,263 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 15, 2025 | Option exercise | +513 | – | – | 8,447 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 15, 2025 | Tax withholding | −178 | $80.67 | $14.36K | 7,934 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 15, 2025 | Option exercise | +496 | – | – | 8,112 |
| Douglas Kirk Ways Interim Chief Medical Officer, Director | Dec 11, 2025 | Option exercise | +1,250 | – | – | 1,250 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 11, 2025 | Tax withholding | −680 | $88.41 | $60.12K | 7,616 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 11, 2025 | Option exercise | +1,900 | – | – | 8,296 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 11, 2025 | Option exercise | +4,950 | – | – | 15,192 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 11, 2025 | Tax withholding | −2,194 | $88.41 | $193.97K | 12,998 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 10, 2025 | Tax withholding | −184 | $85.67 | $15.76K | 6,396 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 10, 2025 | Option exercise | +514 | – | – | 6,580 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2025 | Option exercise | +1,196 | – | – | 10,670 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2025 | Tax withholding | −428 | $85.67 | $36.67K | 10,242 |
| Samir M. Gharib PRESIDENT AND CFO | Oct 20, 2025 | Tax withholding | −661 | $148.16 | $97.93K | 6,066 |
| Samir M. Gharib PRESIDENT AND CFO | Oct 20, 2025 | Option exercise | +2,053 | – | – | 6,727 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Oct 20, 2025 | Tax withholding | −1,539 | $148.16 | $228.02K | 9,474 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Oct 20, 2025 | Option exercise | +4,784 | – | – | 11,013 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Sale | −25 | $17.46 | $437 | 1,050 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Buy | +256 | $17.91 | $4.58K | 1,307 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Sale | −232 | $19.33 | $4.48K | 1,075 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Buy | +256 | $17.91 | $4.58K | 1,307 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Sale | −25 | $17.46 | $437 | 1,050 |
| Healthcare Partners LLC Parkman 10% owner | Oct 6, 2025 | Sale | −232 | $19.33 | $4.48K | 1,075 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 16, 2024 | Option exercise | +26,600 | – | – | 150,409 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 16, 2024 | Option exercise | +31,750 | – | – | 172,668 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 16, 2024 | Tax withholding | −9,491 | $0.39 | $3.70K | 140,918 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 16, 2024 | Tax withholding | −11,329 | $0.39 | $4.42K | 161,339 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 16, 2024 | Tax withholding | −13,291 | $0.39 | $5.18K | 350,550 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 16, 2024 | Option exercise | +38,500 | – | – | 340,328 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 16, 2024 | Option exercise | +37,250 | – | – | 363,841 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 16, 2024 | Tax withholding | −13,737 | $0.39 | $5.36K | 326,591 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Option exercise | +89,700 | – | – | 427,801 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Tax withholding | −32,005 | $0.39 | $12.48K | 395,796 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Option exercise | +111,000 | – | – | 506,796 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 16, 2024 | Tax withholding | −39,605 | $0.39 | $15.45K | 467,191 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 10, 2024 | Option exercise | +106,400 | – | – | 161,773 |
| Ralph William Charlton III CHIEF MEDICAL OFFICER | Dec 10, 2024 | Tax withholding | −37,964 | $0.54 | $20.50K | 123,809 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 10, 2024 | Option exercise | +154,000 | – | – | 356,776 |
| Samir M. Gharib PRESIDENT AND CFO | Dec 10, 2024 | Tax withholding | −54,948 | $0.54 | $29.67K | 301,828 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2024 | Tax withholding | −128,020 | $0.54 | $69.13K | 338,101 |
| Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER, Director | Dec 10, 2024 | Option exercise | +358,800 | – | – | 466,121 |
| Holdings A/S Novo 10% owner | Mar 21, 2024 | Sale | −465,021 | $0.75 | $348.77K | 2,550,000 |
| Holdings A/S Novo 10% owner | Mar 20, 2024 | Sale | −359,979 | $0.73 | $262.78K | 3,015,021 |
| Holdings A/S Novo 10% owner | Mar 19, 2024 | Sale | −593,000 | $0.76 | $450.68K | 3,375,000 |
| Holdings A/S Novo 10% owner | Mar 18, 2024 | Sale | −842,020 | $0.77 | $648.36K | 3,968,000 |
| Holdings A/S Novo 10% owner | Mar 14, 2024 | Sale | −1,912,316 | $0.89 | $1.70M | 4,810,020 |
| Samir M. Gharib President & CFO | Dec 29, 2023 | Award | +11,255 | $0.98 | $11.03K | 202,776 |
| Ralph William Charlton III Chief Medical Officer | Dec 29, 2023 | Award | +9,361 | $0.98 | $9.17K | 55,373 |
| Javier B. Szwarcberg Chief Executive Officer, Director | Dec 15, 2023 | Option exercise | +111,000 | – | – | 145,705 |
| Javier B. Szwarcberg Chief Executive Officer, Director | Dec 15, 2023 | Tax withholding | −38,384 | $1.66 | $63.72K | 107,321 |
| Ralph William Charlton III Chief Medical Officer | Dec 15, 2023 | Option exercise | +31,750 | – | – | 56,992 |
| Ralph William Charlton III Chief Medical Officer | Dec 15, 2023 | Tax withholding | −10,980 | $1.66 | $18.23K | 46,012 |
| Samir M. Gharib President & CFO | Dec 15, 2023 | Tax withholding | −23,213 | $1.66 | $38.53K | 167,153 |
| Samir M. Gharib President & CFO | Dec 15, 2023 | Option exercise | +75,000 | – | – | 190,366 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
65.33%
1M shares short
Days to cover
7.0
At 0M shares a day
Change since last report
+1.8%
From 1M shares
Short volume, 20 days
62.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Spruce Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,227 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Holdings A/S Novo 10% Stockholder | Mar 18, 2024 | 4,810,020 | $3.90M | Mar 18, 2024 | Conversion of Series A Preferred Stock in Initial Public Offering |
| Holdings A/S Novo 10% Stockholder | Mar 14, 2024 | 1,912,316 | $9.49M | Mar 14, 2024 | Conversion of Series A Preferred Stock in Initial Public Offering |
See a number that looks wrong?